Research programme: G-protein coupled receptor modulators - Regeneron
Latest Information Update: 22 Dec 2021
At a glance
- Originator Regeneron Pharmaceuticals
- Class Single-domain antibodies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 15 Dec 2021 Confo Therapeutics has patent protection for methods for screening GPCRs using ConfoBodies®, GPCR-ConfoBody® complexes, developments of the ConfoBody® platform in ConfoScreen®, ConfoSensor®, ConfoChimer™ and ConfoStructure™ technologies in USA and European Union
- 15 Dec 2021 Confo Therapeutics has patent protection for Confo® technology platform in more than 10 patent families worldwide (Confo Therapeutics website, December 2021)
- 06 Dec 2021 Confo Therapeutics and Regeneron entered into a collaborative agreement to discover novel therapeutic antibody drug candidates